| Literature DB >> 26649330 |
William D Harrison1, Deborah Lees1, Jamie A'Court1, Thomas Ankers1, Ian Harper1, Dominic Inman1, Mike R Reed1.
Abstract
Background. An analgesic enhanced recovery (ER) protocol for patients with a hip fracture was introduced. It was hypothesised that the ER would reduce pain, length of stay and improve clinical outcomes. The protocol used intraoperative infiltration of levobupivacaine followed by ongoing wound infusions. Methods. Consecutive patients admitted to two hospitals were eligible for the ER protocol. Numerical Reporting Scale pain scores (0-10) were recorded alongside opiate requirements. 434 patients in the ER group (316 full ER, 90 partial ER, and 28 no ER) were compared to a control group (CG) of 100 consecutive patients managed with traditional opiate analgesia. Results. Mean opiate requirement was 49.2 mg (CG) versus 32.5 mg (ER). Pain scores were significantly reduced in the full ER group, p < 0.0001. Direct discharge home and mean acute inpatient stay were significantly reduced (p = 0.0031 and p < 0.0001, resp.). 30-day mortality was 15% (CG) versus 5.5% (ER), p = 0.0024. Conclusions. This analgesic ER protocol for patients with a hip fracture was safe and effective and was associated with reduced inpatient stay and mortality.Entities:
Year: 2015 PMID: 26649330 PMCID: PMC4663367 DOI: 10.1155/2015/316817
Source DB: PubMed Journal: Surg Res Pract ISSN: 2356-6124
Patient demographics, mechanism of injury, fracture pattern, and management.
| Control group | Enhanced recovery period | |
|---|---|---|
|
| 100 | 434 |
| Age mean | 78.5 years | 82.2 years |
| (Range) | (45–99) | (44–100) |
| Gender | ||
| Male | 24 (24.0%) | 108 (24.8%) |
| Female | 76 (76.0%) | 326 (75.2%) |
| Inpatient confusion | 31 (31.0%) | 177 (40.1%) |
| Injury details | ||
| Slip/trip | 43 (43.0%) | 191 (44%) |
| Collapse | 4 (4.0%) | 25 (5.8%) |
| Activity related | 3 (3.0%) | 49 (11.3%) |
| Slip on ice | 0 (0.0%) | 8 (1.8%) |
| Intoxicated | 1 (1.0%) | 7 (1.6%) |
| Fall in hospital | 4 (4.0%) | 9 (2.1%) |
| Assaulted | 1 (1.0%) | 0 (0%) |
| Unknown | 41 (41.0%) | 132 (30.4%) |
| Pathological | 3 (3.0%) | 13 (3.0%) |
| Fracture type | ||
| Intracapsular | 59 (59.0%) | 239 (55.1%) |
| Extracapsular | 35 (35.0%) | 133 (30.6%) |
| Basicervical | 4 (4.0%) | 42 (9.7%) |
| Pertrochanteric | 0 (0.0%) | 14 (3.2%) |
| Subtrochanteric | 2 (2.0%) | 5 (1.2%) |
| Greater trochanter | 0 (0.0%) | 1 (0.2%) |
| Side | ||
| Bilateral | 0 (0.0%) | 1 (0.2%) |
| Left | 48 (48.0%) | 217 (50%) |
| Right | 52 (52.0%) | 216 (49.8%) |
| FICB given? | ||
| Yes | NA | 326 (75.1%) |
| No | NA | 108 (24.9%) |
| Procedure | ||
| Nonoperative | 2 (2.0%) | 7 (1.6%) |
| Cannulated screws | 7 (7.0%) | 20 (4.6%) |
| Dynamic hip screw | 26 (26.0%) | 144 (33.2%) |
| Intramedullary fixation | 16 (16.0%) | 17 (3.9%) |
| Cemented bipolar hemiarthroplasty | 2 (2.0%) | 3 (0.7%) |
| Cemented Exeter hemiarthroplasty | 11 (11.0%) | 49 (11.3%) |
| Cemented Thompson's hemiarthroplasty | 29 (29.0%) | 183 (42.2%) |
| Uncemented Austin Moore hemiarthroplasty | 1 (1.0%) | 0 (0%) |
| Cemented Austin Moore hemiarthroplasty | 3 (3.0%) | 0 (0%) |
| Uncemented THR | 1 (1.0%) | 0 (0%) |
| Cemented THR | 2 (2.0%) | 15 (3.5%) |
| Enhanced recovery | ||
| None | 100 (100%) | 28 (6.5%) |
| Full ER | NA | 316 (72.8%) |
| LIA only | NA | 75 (17.3%) |
| CATH only | NA | 15 (3.5%) |
| Reasons for partial/no enhanced recovery | ||
| Total | NA | 118 (27.2%) |
| Renal impairment | NA | 44 (10.1%) |
| Catheter pulled out by patient | NA | 6 (1.4%) |
| Catheter blocked | NA | 8 (1.8%) |
| Femoral nerve block given | NA | 27 (6.2%) |
| Reason not documented | NA | 31 (7.1%) |
| Previous adverse drug reaction to local anaesthetic | NA | 2 (0.4%) |
Patient outcomes for the control group and the enhanced recovery cohort.
| Control group | Enhanced recovery cohort | |
|---|---|---|
|
| 100 | 434 |
| Length of stay, mean (range) | ||
| Orthopaedic ward | 15 (3–114) days | 10 (3–44) days |
| Rehabilitation | 15 (1–64) days | 15 (1–114) days |
| Sum duration for a 100-patient group | 1680 days | 1470 days |
| Discharge destination | ||
| 30-day mortality | 15 (15%) | 24 (5.5%) |
| Own home | 52 (52%) | 162 (37.3%) |
| Rehabilitation | 12 (12%) | 138 (31.8%) |
| Care home | 21 (21%) | 110 (25.3%) |
Subgroup analysis of management options and patient outcomes. Patients with cognitive impairment are excluded.
| Control group | Enhanced recovery period | |||
|---|---|---|---|---|
| Full ER | LIA only | CATH only | ||
|
| 79 | 230 | 49 | 15 |
| Discharge destination | ||||
| 30-day mortality | 7 (8.8%) | 0 (0%) | 3 (6.1%) | 4 (26.7%) |
| Own home | 43 (54.4%) | 168 (73%) | 31 (63.3%) | 2 (13.3%) |
| Care facility | 29 (36.7%) | 62 (27%) | 15 (30.6%) | 9 (60%) |
| Length of stay in days | ||||
| Ortho. ward (mean) | 15 | 9 | 9 | 10 |
| Rehab (mean) | 19 | 17 | 17 | 18 |
| Total | 34 (3–114) | 26 (3–80) | 26 (3–88) | 28 (3–82) |
Figure 1Numerical Reporting Scale (NRS) pain scores for the control group and the enhanced recovery subgroups.
Opiate requirement for the control group versus the enhanced recovery protocol. Patients with cognitive impairment are excluded.
| Control group | Enhanced recovery period | |||
|---|---|---|---|---|
| ER | LIA only | CATH only | ||
|
| 100 | 230 | 49 | 15 |
| Cumulative mean | 49.2 mg | 31.8 mg | 37.8 mg | 46 mg |
| (Range) | (0–80 mg) | (0–98 mg) | (0–82 mg) | (3–55 mg) |